Current and Emerging Therapeutics for Cutaneous T-Cell Lymphoma: Histone Deacetylase Inhibitors
Table 1
TMN staging system. Clinical staging system for cutaneous T-cell lymphoma.This classification is designed to select the appropriate treatment at the variant stages of the lymphoma [15–17].
T1
Plaques and/or patches <10% body surface area
T2
Plaques and/or patches ≥10% body surface area
T3
≥1 cutaneous tumours
T4
Erythroderma
NN0
No lymph nodes involved
N1
Lymph nodes enlarged without histological involvement
N2
Nonpalpable lymph nodes with histological involvement
N3
Enlarged lymph nodes with histological involvement
M0
No visceral disease
M1
Visceral disease
B0
No haematological involvement—no atypical (Sézary) cells, <5%
B1
Atypical (Sézary) cells circulating, ≥5% of total peripheral lymphocytes
